TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04661618

Intervention type: DEVICE
Group type: OTHER
Intervention: Gym Tonic programme and Gym equipment
Description: 12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gym Tonic programme and Gym equipment
Description: 12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
Study: NCT00625729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
Study: NCT01927861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
Study: NCT03325803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study: NCT04481009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administrated each 21-day cycle.
Study: NCT04587180

Intervention type: PROCEDURE
Intervention: Arthroscopic suture-bridge rotator cuff repair
Description: Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.

Intervention type: PROCEDURE
Intervention: Arthroscopic suture-bridge rotator cuff repair
Description: Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
Study: NCT05559333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I restoration placement
Description: zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
Study: NCT05559333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I restoration placement
Description: zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I restoration placement
Description: zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I restoration placement
Description: zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
Study: NCT03325803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study: NCT02100033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Study: NCT04074707

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Labeled iron solution (60mg and 120mg Ferrous Fumarate)
Description: 3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
Study: NCT00125385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
Study: NCT04338620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab、albumin-bound paclitaxel and platinum
Description: Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel and platinum
Description: Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin
Study: NCT03955185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgery
Description: Laparoscopic or robotic assisted radical hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open abdominal surgery
Description: Traditional open abdominal radical hysterectomy
Study: NCT05554224

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose diagnostic tests for liver diseases before surgical decisions.
Description: Observational although patients are candidates for metabolic surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose diagnostic tests for liver diseases before surgical decisions.
Description: Observational although patients are candidates for metabolic surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: To propose diagnostic tests for liver diseases before surgical decisions.
Description: Observational although patients are candidates for metabolic surgery.
Study: NCT04204252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha 1-Antitrypsin
Description: Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
Study: NCT05309746

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
Study: NCT00247390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
Study: NCT02163408

Intervention type: OTHER
Intervention: MRI with/without contrast
Description: Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
Study: NCT02453412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVF-simulation
Description: A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
Study: NCT02961764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin
Description: Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
Study: NCT01430221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Personalized Health Planning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured & Guided Education
Study: NCT03333369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg levodopa/50 mg benserazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Study: NCT02242539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Height measurement poster
Description: Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based monitoring
Description: Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day.
Study: NCT00469014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.
Study: NCT03760068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYL-1601D Product
Description: (100 U/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FlexPen NovoLog®
Description: (100 U/mL)
Study: NCT04044287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 micrograms of misoprostol
Description: 200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
Study: NCT02831036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training program
Description: subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.

Intervention type: OTHER
Group type: OTHER
Intervention: VO2max test
Description: each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VO2max test
Description: each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.

Intervention type: OTHER
Group type: OTHER
Intervention: spatial orientation test
Description: each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spatial orientation test
Description: each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
Study: NCT01871727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777 9 mcg/kg
Description: administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
Study: NCT00469014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Infusion
Description: Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
Study: NCT01622127

Intervention type: DEVICE
Intervention: Parietex ProGrip™
Description: ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
Study: NCT00599781

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene transduced PBL and/or gene transduced HSC
Description: infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
Study: NCT00475475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: glucose
Description: 25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: non-caloric sweetener
Description: 25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
Study: NCT04008043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicodin
Description: In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Study: NCT03251677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedure, Hysterectomy
Description: Surgical removal of the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedure, Hysterectomy
Description: Surgical removal of the uterus
Study: NCT01070797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-virus Specific T cells
Description: Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-virus Specific T cells
Description: Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days.
Study: NCT02515812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I-123-MIBG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123-MIBG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CZT Camera (D-SPECT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anger Camera
Study: NCT02519387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Patch